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Therapeutic Effect of Targeting Branched-Chain Amino Acid Catabolic
Flux in Pressure-Overload Induced Heart Failure
Mengping Chen, BS;* Chen Gao, PhD;* Jiayu Yu, BS; Shuxun Ren, MD, PhD; Menglong Wang, MD, PhD; R. Max Wynn, PhD;
David T. Chuang, PhD; Yibin Wang, PhD; Haipeng Sun, PhD
Background-—Branched-chain amino acid (BCAA) catabolic defect is an emerging metabolic hallmark in failing hearts in human and
animal models. The therapeutic impact of targeting BCAA catabolic flux under pathological conditions remains understudied.
Methods and Results-—BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid), a small-molecule inhibitor of branched-chain
ketoacid dehydrogenase kinase, was used to enhance BCAA catabolism. After 2 weeks of transaortic constriction, mice with
significant cardiac dysfunctions were treated with vehicle or BT2. Serial echocardiograms showed continuing pathological
deterioration in left ventricle of the vehicle-treated mice, whereas the BT2-treated mice showed significantly preserved cardiac
function and structure. Moreover, BT2 treatment improved systolic contractility and diastolic mechanics. These therapeutic
benefits appeared to be independent of impacts on left ventricle hypertrophy but associated with increased gene expression
involved in fatty acid utilization. The BT2 administration showed no signs of apparent toxicity.
Conclusions-—Our data provide the first proof-of-concept evidence for the therapeutic efficacy of restoring BCAA catabolic flux in
hearts with preexisting dysfunctions. The BCAA catabolic pathway represents a novel and potentially efficacious target for
treatment of heart failure. ( J Am Heart Assoc. 2019;8:e011625. DOI: 10.1161/JAHA.118.011625.)
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D espite the significant advances in therapies and pre-vention, heart failure still remains a major public health
problem, affecting an estimated 26 million people world-
wide,1,2 with a 25% to 40% 1-year mortality rate.3 Thus, there
is a clear unmet need for new strategies to treat heart failure
and improve the quality of life for patients with systolic
dysfunction.
Pathogenesis of heart failure is associated with metabolic
remodeling and impaired energetics, often characterized by
decreased fatty acid oxidation and increased reliance on
glucose use.4,5 Disturbances in myocardial substrate use and
loss of fuel flexibility lead to energy deficiency in diseased
hearts and ultimately contribute to systolic and diastolic
dysfunctions. Genetic and pharmaceutical modulations of
glucose and fatty acid metabolism have been shown to
influence the progression of cardiac dysfunction in heart
diseases,5–7 implicating regulating cardiac metabolism as a
therapeutic strategy to treat heart failure.
In addition to the current paradigm of lipid and glucose use
in healthy and diseased hearts, emerging lines of evidence
suggest that branched-chain amino acid (BCAA) catabolic
defect is also a major metabolic hallmark in diseased
hearts.8–10 BCAAs, including leucine, isoleucine, and valine,
are essential amino acids for mammals. In addition to de novo
protein synthesis, BCAAs also act as important nutrient signal
molecules to regulate cellular metabolism and growth.11–13
The homeostasis of BCAAs is controlled by their catabolic
pathway, including a shared first deamination step to
branched-chain a-ketoacids (BCKAs) by branched-chain
amino-transferase (BCAT), followed by an irreversible
and rate-limiting catabolic step via BCKDH (branched-chain
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a-ketoacid dehydrogenase) complex. Recent studies show
that BCAA catabolism is impaired in diseased hearts,
accompanied with the downregulation of key catabolic
enzyme expression.8,10 Furthermore, BCAA catabolic defect
is a significant contributor to heart failure progression, at
least in part caused by elevated reactive oxygen species and
metabolic disturbance.8 Accumulated BCAA in hearts sup-
presses the glucose metabolism and augments the ischemia-
reperfusion injury.14 These findings highlight the importance
of BCAA metabolism in maintaining cardiac function in
response to pathological stress.
BCKA dehydrogenase activity is regulated by the phospho-
rylation status of its regulatory subunit E1a.15,16 Branched-
chain ketoacid dehydrogenase kinase (BCKDK) phosphorylates
E1a to inhibit the BCKA dehydrogenase activity.17 Protein
phosphatase 2C in mitochondria (PP2Cm) does the opposite.
BCKDK expression is unaffected or increased in diseased
hearts in contrast to the other suppressed BCAA catabolic
genes, contributing to the BCAA catabolic defect.8,10 BT2 (3,6-
dichlorobenzo[b]thiophene-2-carboxylic acid) is a highly speci-
fic small-molecule BCKDK inhibitor that enhances BCAA
catabolic flux by blocking BCKA dehydrogenase phosphoryla-
tion.18 Two recent studies reported protective effects of BT2
compound on heart function in pressure-overload and myocar-
dial infarction mouse models,8,10 in which the BT2 treatment
started from the onset of surgical operation before patholog-
ical features emerged. However, in clinical practice, therapeu-
tic intervention usually begins when symptoms of heart
dysfunction have developed. Therefore, it is persuasive to
ask whether the benefits of BT2 treatment could be achieved
in hearts with preexisting pathological changes.
In the present study, we sought to elucidate the
therapeutic efficacy of restoring BCAA catabolic flux through
pharmacological inhibition of BCKDK in heart failure. Our
results showed BCKDK inhibition preserved systolic contrac-
tility and diastolic mechanics, and it significantly blunted
further pathological deterioration in hearts with preexisting
dysfunctions. These findings highlight the therapeutic poten-
tial of targeting BCAA catabolism to treat heart failure.
Methods
The authors declare that all supporting data are available
within the article. Requests for detailed analytic methods will
be addressed by the corresponding author.
An expanded methods section is available in Data S1.
Animals
Wild-type male C57BL/6N mice were purchased from ENVIGO
and housed at 22°C with a 12-hour light, 12-hour dark cycle
with free access to water and standard chow. Terminal tissue
collection was performed on mice under isoflurane anesthesia
with additional cervical dislocation. All animal procedures
were performed in accordance with the National Institutes of
Health guidelines and protocols approved by the University of
California at Los Angeles Institutional Animal Care and Use
Committee.
Transverse Aortic Constriction
Transverse aortic constriction (TAC) was performed, as
described,19 in anesthetized (pentobarbital, 60 mg/kg, IP)
and ventilated mice (aged 6–8 weeks) to induce hypertrophy
and heart failure. After left anterolateral thoracotomywith blunt
dissection through the intercostal muscles, aortic constriction
was induced by ligating the transverse aorta around a 27.5-
gauge blunt needle using 6-0 silk suture. The needle was
subsequently removed. Sham-operated mice underwent a
similar surgical procedure without constriction of the aorta.
All mice were maintained in the same environment with regular
laboratory chow and water ad libitum. At the end of the
experiments, animals were euthanized by cervical dislocation,
and the hearts and other organs were removed and weighed.
Hearts were dissected, and tissues were either immediately
immersed into 4% buffered formaldehyde or quickly frozen in
liquid nitrogen for further experiments.
Mouse Study With BT2 Treatment
Compound BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic
acid) was a kind gift from the laboratory of Dr David T. Chuang
(University of Texas Southwestern Medical Center, Dallas, TX).
BT2 was dissolved in dimethyl sulfoxide and diluted into 5%
dimethyl sulfoxide, 10% cremophor EL, and 85% 0.1 mol/L
sodium bicarbonate, pH 9.0, buffer for delivery. Vehicle buffer
contained the same components without BT2 compound.
Administration of vehicle or BT2 was performed, as previously
described,18 except that animals (aged 6–8 weeks) were dosed
daily by oral gavage at 40 mg/kg per day. C57BL/6N adult
male mice (n=21) were subjected to TAC to provoke hypertro-
phy and contractile dysfunction, and echocardiography was
performed to confirm left ventricular (LV) contractility and
Clinical Perspective
What Is New?
• This is the first study that demonstrates the therapeutic
efficacy of enhancing branched-chain amino acid catabolism
in hearts with preexisting dysfunctions.
What Are the Clinical Implications?
• Branched-chain amino acid catabolism is a promising
therapeutic target for the treatment of heart failure.
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cardiac dysfunction. At 2 weeks after TAC, 4 mice died.
Seventeen survival mice were then intragastrically adminis-
tered a BCKDK inhibitor BT2 (n=9) or vehicle (n=8) for 6 weeks,
and cardiac function was assessed every week. C57BL/6N
adult male mice (n=6) were subjected to sham operation, and
2 weeks later, they were randomized to vehicle (n=3) or BT2
(n=3) treatment for an additional 6 weeks. At the end of the
experiments (8 weeks after TAC or sham), mice were
euthanized by cervical dislocation, and the hearts were
collected for further biomolecular analyses.
Neonatal Rat Ventricular Myocyte Culture and
BT2 Treatment
Neonatal rat ventricular myocytes (NRVMs) were prepared
from 2-day-old Sprague Dawley rats by enzymatic digestion
with collagenase and pancreatin in 19 ADS buffer at 37°C, as
described previously.20 NRVMs were cultured in serum-free
DMEM supplemented with 100 U/mL penicillin/streptomycin
and 5% ITS (insulin-transferrin-selenium) (w/v). NRVMs were
exposed to phenylephrine (100 lmol/L) for 24 hours, and
then further treated with BT2 (80 lmol/L, dissolved in
dimethyl sulfoxide) or 0.1% dimethyl sulfoxide as control for
an additional 24 hours.
Echocardiography
The mice were anesthetized and maintained with 1% to 2%
isoflurane in 95% oxygen. Echocardiography was performed
with a VisualSonics Vevo 2100 instrument (VisualSonics Inc,
Toronto, ON, Canada) equipped with a 30-MHz linear trans-
ducer. A parasternal short-axis view was used to obtain M-
mode images for analysis of fractional shortening (FS),
ejection fraction (EF), and other cardiac parameters.
Speckle-tracking echocardiography was performed, as
described previously.21 Strain analyses were conducted by
the same trained investigator (M.C.) on all animals using a
speckle-tracking algorithm provided by VisualSonics (VevoS-
train). In brief, suitable B-mode loops were selected from
digitally acquired echocardiographic images based on ade-
quate visualization of the endocardial border and absence of
image artifacts. Three consecutive cardiac cycles were
selected for analysis, and strain measures were averaged
over the obtained cardiac cycles. Each long- and short-axis
view of the LV myocardium was divided into 6 standard
anatomic segments, and peak strain and strain rate measure-
ments were averaged across all 6 segments, as well as the
motion measurements (velocity and displacement). Longitu-
dinal strain analyses were obtained from long-axis views,
whereas circumferential and radial strain analyses were
obtained from short-axis views. For the diastolic myocardial
strain analysis, the data presented in this study were the
mean global strain rate values at all 3 axes as well. As
described in a previous study,22 to quantify the peak strain
rate during early LV filling, the “reverse peak” option in the
Vevo2100 1.6.0 Image Software was used, and parameters of
peak reverse strain rate at different planes (longitudinal,
radial, and circumferential) were obtained.
Western Blot Analysis
Proteins from heart tissue were harvested in buffer
(50 mmol/L HEPES [pH 7.4], 150 mmol/L NaCl, 1% NP-40
(nonyl phenoxypolyethoxylethanol-40), 1 mmol/L EDTA,
1 mmol/L EGTA, 1 mmol/L glycerophosphate, 2.5 mmol/L
sodium pyrophosphate, 1 mmol/L Na3VO4, 20 mmol/L NaF,
1 mmol/L phenylmethylsulfonyl fluoride, and 1 lg/mL of
aprotinin, leupeptin, and pepstatin). Samples were separated
onto 4% to 12% Bis-Tris gels (Invitrogen) and transferred onto
a nitrocellulose blot (Amersham). The blot was probed with
the indicated primary antibodies. Protein signals were
detected using horseradish peroxidase–conjugated secondary
antibodies and enhanced chemiluminescence23 Western
blotting detection reagents (Pierce). Rabbit polyclonal antisera
against the E1a subunit of BCKD complex and phosphorylated
E1a antibody, and GAPDH, H3, and BCKDK antibodies, were
purchased from Abcam. PP2Cm antibody was generated in
the laboratory.
Real-Time Reverse Transcription–Polymerase
Chain Reaction Analysis
Total RNA was extracted from heart tissues using Trizol
Reagent (Invitrogen), according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed into the first-strand
cDNA using ProtoScript II Reverse Transcriptase (New England
BioLabs). Then, cDNA transcripts were quantified by the CFX
Real-TimePCRSystem (BioRad). 18S ribosomalRNAswereused
for normalization, except where indicated otherwise.
Polymerase chain reaction primer information is available upon
request.
Cardiac BCAA and BCKA Assay
Micewere subjected to TAC for 2 weeks to provoke dysfunction
and then intragastrically administered a BCKDK inhibitor BT2 or
vehicle for an additional 6 weeks. At the end of the experiment,
mice were fasted for 6 hours before tissue collection. Heart
tissues were collected, and LVs were separated and frozen in
liquid nitrogen. Frozen tissue was weighed and homogenized in
a 3-fold volume of PBS using a Bead-Bug homogenizer. Tissue
lysate (50 lL) was precleared of protein by addition of an equal
volume of methanol, followed by 2 rounds of centrifugation to
precipitate protein. The supernatant was lyophilized and
DOI: 10.1161/JAHA.118.011625 Journal of the American Heart Association 3
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resuspended in 30 lL distilled water. For BCAA measurement,
standards (L-valine, L-leucine, L-isoleucine, and L-allo-isoleucine)
were prepared from 10 mmol/L stocks, and serial pooled
dilutions were made (10–2000 lmol/L). A total of 2 lL of
standard or 2 lL of sample was diluted in 50 lL butanolic HCL
and heated to 60℃ for 20 minutes, and then speed-vac was used
to obtain dryness. The samples were resuspended in 200 lL of
(50:50) distilled water/acetonitrile containing 0.1% formic acid.
BCAA concentrations in samples and standard were deter-
mined by liquid chromatography–tandemmass spectrometry in
a 3200 QTRAP mass spectrometer coupled to a Shimadzu
Prominence liquid chromatographic instrument. An Agilent
C18XDB 5 µm packing column (5094.6 mm) was used for
chromatographywith the following conditions: buffer A, distilled
water+0.1% formic acid; buffer B, acetonitrile+0.1% formic acid;
flow rate, 1.0 mL/min. BCAA concentrations in vehicle- or BT2-
treated heart samples were determined on the basis of the
standard curve. BCKA measurements were performed, as
described elsewhere.24 Briefly, the perchloric acid heart super-
natantswere derivatizedby o-phenylenediamine, extractedwith
ethyl acetate, and dried down in glass tubes in an unheated
vacuum centrifuge. After drying, the ketoacids were reconsti-
tuted in 200 mmol/L ammonium acetate, pH 6.8, and analyzed
usingaShimadzuultrafast liquidchromatography20ADXR liquid
chromatographic system in line with an AB-Sciex 3200 QTRAP
mass spectrometer. Both instruments used in this analysiswere
housed in the University of Texas Southwestern Medical Center
Core Facility. BCAA/BCKA concentrations were measured and
normalized to the weight of tissue.
Statistical Analysis
For 2-group comparison, statistical analyses were performed
with Student’s t test. For repeated measurements over time,
as shown in longitudinal echocardiographic analysis, 2-way
ANOVA, followed by Bonferroni’s post hoc test, was per-
formed to evaluate the differences between groups over time
or at each time point. For multiple group comparison,
differences were analyzed by 1- or 2-way ANOVA with
Bonferroni’s method. All data were presented as meanSEM
or meanSD, and were analyzed using GraphPad Prism 7
software (GraphPad Software). P<0.05 was considered as
statistically significant.
Results
Establishment of a Mouse Model With Preexisting
Cardiac Dysfunction for Subsequent
Pharmacological Treatment
Often, patients present to medical attention at the time of
symptom development. As such, preventing the further
deterioration of existing pathological conditions is the major
objective of therapeutic intervention. To assess the thera-
peutic impacts of restoring BCAA catabolism on the
progression of heart failure, pressure overload to LV was
initiated by TAC for 2 weeks, followed by treating the
animals with BT2 (a small-molecule inhibitor of BCKDK) or
vehicle via oral gavage for additional 6 weeks (Figure 1A and
1B). Before the BT2 treatment, echocardiography detected
robust hypertrophic growth with dramatically increased LV
mass and ventricular dilatation and significant declines in
systolic function in hearts with aortic stricture (Figure 1C, D,
E, F). Mice were then randomly assigned to receive BT2
(40 mg/kg per day) or vehicle treatment. As expected, BT2
treatment significantly reduced BCKDK-mediated BCKDE1a
(branched-chain ketoacid dehydrogenase subunit E1a) phos-
phorylation without significantly affecting BCKDK protein
expression (Figure 1G and 1H). Cardiac intratissue concen-
trations of BCAAs and BCKAs were significantly reduced
(Figure 1I and 1J), consistent with the enhanced BCAA
catabolic activities.
BCKDK Inhibitory Treatment Alleviated
Pressure-Overload Induced Systolic Dysfunction
Without Affecting Hypertrophy
To assess responses in individual mouse, we measured FS and
EF at each time point and calculated ΔFS and ΔEF of each
mouse using parameters at 2 weeks after TAC (time right
before drug treatment) as baseline (defined as 0); then, the
average ΔFS and ΔEF at each time point were plotted.
Through this approach, minus ΔFS or ΔEF indicated worsened
systolic function, whereas plus values indicated improvement
(Figure 2A and 2B). After 2 weeks of treatment (4 weeks after
TAC), BT2-treated mouse hearts started to show an improve-
ment of systolic performance, as indicated by positive values
of ΔFS and ΔEF. Six weeks of BT2 treatment led to well-
preserved cardiac functions, whereas progressive deteriora-
tion of cardiac dysfunction was observed in vehicle-treated
animals, as indicated by the continuous reduction of FS and EF
during the treatment period (Figure 2A and 2B, Figure S1A
and S1B). Similar analyses of structural measurements
showed preserved chamber structure in BT2-treated mouse
hearts, as seen in approximately unchanged ΔLV internal
dimensions (Figure 2C, Figure S1C) and ΔLV volume (Fig-
ure 2D, Figure S1D). In contrast, vehicle-treated animals
developed significant chamber dilatation, as indicated by
continuous increases of LVID and LV volume during the
treatment period. BT2 treatment did not affect cardiac
hypertrophy, indicated by heart weights (Figure 2E), hyper-
trophic marker expression (Figure 2F), and LV posterior wall
thickness (Table S1). Heart rate was not affected by BT2
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Figure 1. Establishment of a mouse model with preexisting cardiac dysfunction for subsequent pharmacological treatment. A, Schematic
timeline and experimental design. C57BL/6N adult male mice (n=21) were subjected to transverse aortic constriction (TAC) to provoke
hypertrophy and contractile dysfunction, and echocardiography was performed to confirm left ventricular (LV) contractility and cardiac
dysfunction. Four mice died before drug treatment. Mice were then intragastrically administered with BT2 (n=9) or vehicle (n=8) for 6 weeks, and
cardiac function was assessed every week. B, A schematic illustration of key enzymes and regulators involved in branched-chain amino acid
(BCAA) catabolism. C through F, Echocardiographic parameters in the first 2 weeks after TAC. Average values of LV ejection fraction (EF; C), LV
mass (D), LV internal diameter at systole (LVID;s; E), and LV volume at systole (LV Vol;s; F) obtained from echocardiography are shown.
G through J, Analyses of hearts at 8 weeks after TAC procedure (n=5 in vehicle group, n=7 in BT2 group). G, Expression of total, phosphorylated
branched-chain ketoacid dehydrogenase (BCKD) subunit E1a, and BCKD kinase (BCKDK) in mouse heart was determined by Western blotting.
H, The relative phosphorylated E1a level and BCKDK level were calculated. Cardiac BCAA (I) and branched-chain a-ketoacid (BCKA; J) abundances
were measured, as described in Methods. For data of Figure 1C and 1F, comparison of indicated time points vs baseline was analyzed by 1-way
ANOVA with Bonferroni’s test. For Figure 1H and 1J, differences were evaluated by Student’s t test. Data were presented as meanSEM. BCAT
indicates branched-chain amino-transferase; BCKDH, branched-chain ketoacid dehydrogenase; KIC, a-ketoisocaproic; KMV, a-keto-b-
methylvaleric; KIV, a-ketoisovaleric; Suc-CoA; Succinyl-CoA. *P<0.05.
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treatment (Table S2). Together, these data demonstrate that
BCKDK inhibitory treatment is capable of attenuating existing
systolic dysfunction.
BCKDK Inhibitory Treatment Preserved
Myocardial Contractile Function
Conventional echocardiographic measures, such as EF and
FS, lack sensitivity for capturing subtle changes in LV
ventricular performance and fail to detect early myocardial
dysfunction.25 Recent studies have reported that mechanical
indexes derived from strain analysis provide more accurate
and sensitive measurement of myocardial contractile func-
tion.25–27 To fully describe the impact of BT2 treatment on
murine myocardium contractile function in the setting of heart
failure, we took advantage of a 2-dimensional speckle-
tracking echocardiography technique to measure myocardial
mechanics, including deformation (strain and strain rate) and
wall motion (velocity and displacement). Consistent with the
conventional echocardiographic measurements, BT2 treat-
ment significantly improved myocardial strain (Figure 3A and
3B) and strain rate (Figure 3C and 3D) in both longitudinal and
radial axes. Furthermore, BT2 treatment increased systolic
velocity and displacement in both longitudinal and radial
planes (Figure 3E, F, G, H), indicating that BT2 significantly
Figure 2. Inhibition of branched-chain a-ketoacid dehydrogenase kinase (BCKDK) by BT2 preserved systolic
function in hearts with preexisting dysfunctions. Mice were subjected to transverse aortic constriction (TAC)
procedure for 2 weeks and then were randomized to be treated with BT2 (n=9) or vehicle (n=8) for an additional
6 weeks. Relative changes of left ventricular (LV) fractional shortening (ΔFS; A), ejection fraction (ΔEF; B), LV
internal diameters (ΔLVID;s; C), and LV volume (ΔLV Vol;s; D) were presented at indicated time points. E, Heart
weight/tibia length (HW/TL) ratios at 8 weeks after TAC procedure were presented (n=5 in vehicle group, n=7 in
BT2 group). F, Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) expression was quantified by
real-time quantitative reverse transcription–polymerase chain reaction (n=5 in vehicle group, n=7 in BT2 group).
For A through D, 2-way ANOVA, followed by Bonferroni’s post hoc test, was performed to evaluate the differences
between groups over the treatment period (from week 3 to week 8). For E and F, Student’s t test was used for
2-group comparison. Data were presented as meanSEM. NS indicates not significant. *P<0.05.
DOI: 10.1161/JAHA.118.011625 Journal of the American Heart Association 6
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improved myocardial wall motion. Together, these data
suggest that BT2 improves myocardial mechanics to preserve
cardiac contractile function under pathological stress.
BT2 Treatment Improved Diastolic LV Mechanics
Several previous investigations suggest that early diastolic
strain rate can serve as a novel marker of elevated LV filling
pressure28–30 and contributes to the evaluation of diastolic
function22 and myocardial viability.31–33 We assessed the
effects of BT2 treatment on diastolic myocardial mechanics
in mouse hearts by measuring peak strain rate during early
LV filling through 2-dimensional speckle-tracking echocar-
diography. Compared with vehicle, BT2-treated mouse
hearts displayed a higher longitudinal diastolic strain rate
by 2 weeks of treatment (4 weeks after TAC), and a similar
trend was observed in the subsequent 4 weeks (Figure 4A).
At radial plane, BT2 treatment prevented the reduction of
radial strain rate over the observation period (from week 4
to week 8) (Figure 4B). Furthermore, BT2 treatment pre-
served the diastolic velocity of wall motion (Figure 4C and
4D). Together, these data imply that BT2 preserves diastolic
mechanics to blunt deteriorated myocardial performance
under pathological stress.
Figure 3. Branched-chain a-ketoacid dehydrogenase kinase (BCKDK) inhibitory treatment improved
myocardium contractility and wall motion. Mice were subjected to transverse aortic constriction (TAC)
procedure for 2 weeks and then were randomized to be treated with BT2 (n=9) or vehicle (n=8) for an
additional 6 weeks. Relative global longitudinal strain (GLS; A), global radial strain (GRS; B), and respective
global strain rate (GLSR and GRSR; C and D) for both groups at indicated time points were presented. Means of
systolic velocity (E and F) and displacement (G and H) at longitudinal and radial planes were presented. Two-
way ANOVA, followed by Bonferroni’s post hoc test, was performed to evaluate the differences between groups
over the treatment period (from week 4 to week 8). Data were presented as meanSEM. *P<0.05.
DOI: 10.1161/JAHA.118.011625 Journal of the American Heart Association 7
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BT2 Treatment Altered the Expression of Genes
Involved in Substrate Metabolism
Although the direct contribution of BCAA catabolism to myocar-
dial energetics is limited,4,34,35 disruptive BCAA catabolism
suppresses glucose oxidation, promotes fatty acid oxidation,14
and affects global metabolism.8,10 To investigate the potential
mechanisms underlying the therapeutic benefits of BT2, we
assessed the expression of genes involved in major metabolic
processes inmouse hearts. We also examined the direct impacts
of BT2 on these genes in cultured primary NRVMs treated with or
without phenylephrine (Figure S2). The mitochondrial mass
seemed unchanged because mitochondrial DNA amount
remained unaffected by BT2 treatment in both hearts and
NRVMs (Figure 5A and 5B). Interestingly, although the expres-
sion of genes involved in glucose transport was unaffected, BT2
treatment significantly increased PDK4 (pyruvate dehydrogen-
ase kinase 4) expression in cardiomyocytes and a similar trend
was observed in the hearts (Figure 5C and 5D), which may
indicate a decreased glucose oxidation via PDK4-inhibited
pyruvate dehydrogenase complex. Moreover, mRNA level of
CD36 (cluster of differentiation 36), a key gene for fatty acid
uptake, was increased by BT2 in cardiomyocytes and hearts
(Figure 5E and 5F). In addition, expression of genes involved in
fatty acid b-oxidation (Acox1, Acadl, and Acadm) also showed a
trend of increase in BT2-treated mouse hearts and NRVMs
(Figure 5E and 5F). Collectively, these gene expression data
indicate that BCKDK inhibitory treatment may lead to reduced
glucose oxidation and increased fatty acid use in hearts.
BT2 Treatment Showed No Signs of Apparent
Toxicity
Drug toxicity is a major concern in clinic. To evaluate whether
BT2 treatment resulted in toxic effects, animals were
subjected to sham operation and 2 weeks later randomized
to receive vehicle or BT2 compound for an additional
6 weeks. Echocardiographic measurements showed that
BT2 treatment did not affect the systolic function and
myocardial structure as no significant changes were detected
in EF and LVID between BT2 and vehicle groups (Figure 6A, B,
C). Furthermore, body weight and organ weight were not
affected by BT2 treatment (Figure 6D and 6E). BT2 treatment
reduced BCKDE1a (branched-chain ketoacid dehydrogenase
subunit E1a) phosphorylation (Figure 6F). Together, these
data indicate that BT2 treatment in the current study does not
cause apparent toxicity in mice.
Discussion
The current study explored the therapeutic value of targeting
the BCAA catabolic flux to treat heart failure. After the
Figure 4. Branched-chain a-ketoacid dehydrogenase kinase (BCKDK) inhibitory treatment improved
diastolic left ventricular mechanics. Mice were subjected to transverse aortic constriction (TAC) procedure
for 2 weeks and then were randomized to be treated with BT2 (n=9) or vehicle (n=8) for an additional
6 weeks. Relative diastolic longitudinal strain rate (A) and diastolic radial strain rate (B) for both groups at
indicated time points were presented. Diastolic longitudinal velocity (C) and radial velocity (D) were
presented. Two-way ANOVA, followed by Bonferroni’s post hoc test, was performed to evaluate the
differences between groups over the treatment period (from week 4 to week 8). Data are presented as
meanSEM. *P<0.05.
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establishment of cardiac dysfunction by pressure overload,
animals were subjected to BT2 treatment to enhance BCAA
catabolic flux. The results showed that BT2 compound was
capable of preserving systolic function and alleviating struc-
tural remodeling in mouse hearts with preexisting dysfunc-
tion. These therapeutic benefits were associated with
significantly improved myocardial contractility and diastolic
deformation. Moreover, gene expression analysis indicated
that enhanced BCAA catabolic flux might improve fatty acid
oxidation in the dysfunctional hearts. Finally, BT2 treatment
did not affect the body weight and cardiac function in sham-
operated mice, suggesting the lack of apparent toxicity of BT2
treatment.
Emerging studies report impaired BCAA catabolic activity
in dysfunctional hearts.8–10,36 Previous studies investigated
roles of BCAA catabolism in heart failure progression by
administrating BT2 at the onset of pathological stresses
induced by myocardial infarction or pressure overload.8,10 In
the present study, BT2 is administrated after cardiac
dysfunction and pathological remodeling have been estab-
lished. This design provides a virtual approach to imitate the
situation in clinic in which patients usually seek medical care
after symptoms of cardiac dysfunction develop. The clear
beneficial effects of administrating BT2 in mouse with
preexisting cardiac dysfunction provide the first proof-of-
concept evidence for the therapeutic effects of restoring
BCAA catabolic flux. Therefore, the BCAA catabolic pathway
represents a novel and potentially efficacious target for the
treatment of heart failure.
The accurate assessment of myocardial function is of great
significance for the diagnosis and management of cardiac
dysfunction.37,38 Compared with the conventional parameters
for evaluating cardiac function, strain analysis using 2-
dimensional speckle-tracking echocardiography provides a
tool with more sensitivity and accuracy as it directly detects
the intrinsic mechanical property of myocardium.25,27,29
Because of the complex cardiac geometry, myocardium
conducts multidirectional motion and distortion to perform
proper contraction and relaxation to generate sufficient
cardiac output.39,40 Cardiac performance is partially based
on the intrinsic ability of myocardial fibers to conduct these
physical movements. Thus, myocardial mechanical impair-
ment can result in cardiac dysfunction.41,42 In the present
study, BT2 treatment improved systolic deformation and wall
motion in dysfunctional hearts. And similar effects were also
observed in diastolic strain measurements. These findings
Figure 5. BT2 treatment altered the expression of genes involved in substrate metabolism. A, C, and E, Hearts were collected after 6 weeks of
treatment with either vehicle or BT2 (8 weeks after surgery). B, D, and F, Neonatal rat ventricular myocytes (NRVMs) were treated with vehicle
or phenylephrine (100 lmol/L) for 24 hours, followed by treatments of BT2 (80 lmol/L, dissolved in dimethyl sulfoxide [DMSO]) or 0.1% DMSO
as control for an additional 24 hours. Mitochondrial DNA amounts in mouse hearts (A) and NRVMs (B) were analyzed by quantitative polymerase
chain reaction (PCR) using primers specific for the mitochondrial cytochrome b (CytB) gene and normalized to genomic DNA by amplification of
the large ribosomal protein p0 (36B4) nuclear gene. mRNA expression of genes involved in glucose transportation (Glut1 and Glut4) and
oxidation (PDK4) in mouse hearts (C) and NRVMs (D) was determined by quantitative PCR. mRNA expression of genes involved in fatty acid
transport (CD36) and b-oxidation (Acox1, Acadl, and Acadm) in mouse hearts (E) and NRVMs (F) was analyzed by quantitative PCR. For animal
studies: n=3 for sham-vehicle group, n=3 for sham-BT2 group, n=5 for transverse aortic constriction (TAC)–vehicle group, n=7 for TAC-BT2
group. For NRVM experiment: n=3 for each group. Two-way ANOVA, followed by Bonferroni’s post hoc test, was performed for multiple
comparison. Data were presented as meanSD. NS indicates not significant. *P<0.05.
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suggest that BT2 could preserve myocardial mechanical
function in the setting of heart failure and ultimately improve
LV pump performance, indicating a mechanism underlying the
therapeutic benefits from targeting BCAA catabolic flux.
Fatty acid oxidation is the preferred fuel source in the
healthy myocardium, accounting for  70% of the ATP
generated in the mitochondria. In failing hearts, fatty acid
use is substantially decreased.43 Although whether the
deficiency of fatty acid oxidation contributes to heart failure
remains controversial, several lines of evidence suggest that
enhancing fatty acid oxidation by peroxisome proliferator-
activated receptor a activation44–46 or ACC2 (acetyl-CoA
carboxylase 2) deletion47 is beneficial in heart failure. Our
gene expression data indicate that BT2 treatment may
increase fatty acid use and decrease glucose oxidation. An
early study showed that inhibition of glucose metabolism,
resulting from increased fatty acid oxidation, led to preserved
cardiac function and energetics in stressed heart.47 Therefore,
it is tempting to speculate that the BT2 treatment acts
through optimization of cardiac substrate use to attenuate the
deterioration of heart dysfunction. Additional studies on
myocardial metabolism, including protein levels, enzyme
activities, substrate use analysis, and metabolic fluxes, are
needed to provide more supporting evidence. On the other
hand, BT2 may exert its beneficial effects on heart by
alleviating the oxidative stress via reducing BCKA or reducing
the mTORC1 (mammalian target of rapamycin complex 1)
activity by lowering BCAA.8,10 The molecular mechanisms
underlying the cardioprotective effects observed in these
studies remain to be fully investigated.
Figure 6. BT2 treatment showed no signs of apparent toxicity. Mice were subjected to sham procedure.
Two weeks later, animals were randomized into 2 groups to be treated with either BT2 (n=3) or vehicle (n=3).
Mean left ventricular ejection fraction (EF; A) and left ventricular internal diameter at systole (LVID;s; B) were
obtained from echocardiography. C, Representative M-mode echocardiographs of mouse hearts after sham
procedure, treatedwith either vehicle or BT2.D, Bodyweight (BW) fromboth groups.E, Tissueweight ofmice at
8 weeks after sham procedure. F, Expression of total and phosphorylated branched-chain ketoacid
dehydrogenase subunit E1a (BCKDE1a) in mouse heart at 8 weeks after sham procedure was determined by
Western blot (left). The relative phosphorylated E1a level was calculated (right). For A through C, statistical
analysis was performed using 2-way ANOVA, followed by Bonferroni’s post hoc test. Student’s t test was
performed for E and F. Data were presented as meanSEM. NS indicates not significant. *P<0.05.
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Despite the limited contribution of BCAA metabolism to the
energy supply in heart tissue,4,34,35 increasing lines of
evidence suggest that a defect in BCAA catabolic pathway
is another metabolic hallmark of cardiac hypertrophy and
failure.9,48 The promise of targeting BCAA metabolism for
heart failure therapy has been highlighted in previous
investigations.8,10 The current study clearly demonstrates
the therapeutic effect of BCKDK inhibition by showing BT2 is
capable of preserving myocardial contractility and mechanical
function in hearts with preexisting dysfunctions. Thus,
targeting BCAA catabolic flux provides a novel and promising
therapeutic strategy for the treatment of heart failure.
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SUPPLEMENTAL MATERIAL 
Data S1.
Supplemental Methods 
NRVM culture and BT2 treatment 
Neonatal rat ventricular myocytes (NRVM) were prepared from 2-day old Sprague 
Dawley rat by enzymatic digestion with collagenase and pancreatin in 1×ADS buffer at 
37°C as described previously.1 NRVM were cultured in serum-free DMEM supplemented 
with 100U/ml Pen/Strep and 5% ITS (w/v). NRVM were exposed to PE (phenylephrine, 
100μM) for 24h, and then further treated with BT2 (80μM, dissolved in DMSO) or 0.1%
DMSO as control for additional 24h. 
Statistics analysis 
Statistical analyses were performed using GraphPad Prism 7 software (GraphPad 
Software, UAS). Results were presented as mean±SEM. Differences between groups 
over time were analyzed by two-way ANOVA with Bonferroni’s method. P values less 
than 0.05 were considered as statistically significant. 
Table S1. Left ventricular posterior wall thickness of sham or TAC mice treated with 
vehicle or BT2. 
LVPW;s, mm Sham TAC 
Vehicle BT2 Vehicle BT2 
Baseline 1.1020.052 1.1340.083 0.9810.036 1.0030.419 
Day 3 0.9590.089 1.0070.111 1.0160.039 1.0180.048 
Day 7 1.0150.103 1.0380.035 1.1040.038 1.1040.109 
Day 10 1.0860.112 0.9760.072 1.1380.056 1.1520.029 
Week 2 1.0340.144 1.1080.145 1.1880.046 1.1490.060 
Week 3 0.9880.079 1.0180.113 1.1730.048 1.0930.065 
Week 4 1.0540.128 0.9960.087 1.1840.070 1.1440.061 
Week 5 1.0460.065 1.0180.110 1.1290.083 1.0740.033 
Week 6 1.0340.130 1.1230.095 1.3010.093 1.1990.044 
Week 7 1.0450.120 1.0920.088 1.2330.147 1.2820.050 
Week 8 1.1010.064 1.0450.095 1.1920.160 1.2000.049 
LVPW;d, mm Sham TAC 
Vehicle BT2 Vehicle BT2 
Baseline 0.7030.032 0.6850.015 0.6850.034 0.6570.039 
Day 3 0.6680.093 0.6850.061 0.8220.032 0.8010.046 
Day 7 0.6850.055 0.7130.033 0.9430.041 1.0070.062 
Day 10 0.7010.034 0.6890.035 0.9700.056 0.9460.028 
Week 2 0.6650.051 0.6710.050 1.0380.057 0.9190.059 
Week 3 0.6980.009 0.7010.029 1.0070.033 0.9200.060 
Week 4 0.6750.056 0.6850.042 1.0020.082 0.9610.059 
Week 5 0.6470.039 0.6750.036 0.9200.068 0.9040.037 
Week 6 0.6720.027 0.6560.044 1.1110.080 1.0220.079 
Week 7 0.6790.041 0.7130.018 1.0630.122 1.0620.088 
Week 8 0.6990.015 0.6890.022 1.1100.192 0.9270.038 
Data was presented as mean±SEM. For sham groups, n=3 per group; for TAC groups, 
n=8 in vehicle group, and n=9 in BT2 group. LVPW;s, left ventricular posterior wall end-
systolic thickness; LVPW;d, left ventricular posterior wall end-diastolic thickness. 
Statistical analysis was performed by two-way ANOVA with Bonferroni’s method. No 
significance was observed between vehicle and BT2 groups over time or at each time 
points post sham or TAC procedure. 
Table S2. Heart rate of sham or TAC mice treated with vehicle or BT2. 
Data was presented as mean±SEM. For sham groups, n=3 per group; for TAC groups, 
n=8 in vehicle group, n=9 in BT2 group. Statistical analysis was performed by two-way 
ANOVA with Bonferroni’s method. No significance was observed between vehicle and 
BT2 groups over time or at each time points post sham or TAC procedures. 
Heart rate, 
bpm 
Sham TAC 
Vehicle BT2 Vehicle BT2 
Baseline 506.047.0 50760.0 500.912.9 523.418.9 
Day 3 517.034.6 48447.7 497.911.7 496.19.2 
Day 7 546.735.4 52839.0 482.68.15 491.315.3 
Day 10 487.022.9 511.331.9 514.618.3 503.19.3 
Week 2 520.723.9 496.328.5 482.112.6 512.87.0 
Week 3 483.79.6 479.79.2 477.517.6 481.58.7 
Week 4 537.721.7 5067.2 504.77.1 487.98.8 
Week 5 493.734.0 481.719.8 483.316.4 492.013.5 
Week 6 498.018.3 517.729.7 510.417.3 498.114.1 
Week 7 520.07.0 507.38.4 516.016.7 507.316.9 
Week 8 533.029.5 516.738.8 513.015.6 538.019.4 
Figure S1. Absolute values of echocardiographic parameters before and after BT2 
treatments in pressure-overloaded mouse hearts. Average left ventricular fractional 
shortening (FS) (A) and ejection fraction (EF) (B) for both groups were 
presented at indicated time points. Structural measurements of LV internal diameters 
(LVID;s) (C) and LV volume (LV Vol;s) (D) were presented at indicated time points. Two-
way ANOVA followed by Bonferroni’s post-hoc test was performed to evaluate the 
differences between groups over the treatment period (from week 3 to week 8). *, p<0.05. 
Data was presented as mean±SEM. 
Figure S2.  BT2 treatment led to a decrease of BCKDE1α phosphorylation in NRVM. 
(A) Schematic timeline of primary cardiomyocytes study. NRVM was pretreated with PE 
(100μM) for 24h, and then further exposed to DMSO or BT2 (80μM) for additional 24h. 
Cells were collected and proceeded for further measurements. (B) At day3, NRVM were 
collected and expression of total, phosphorylated BCKD subunit E1α, and GAPDH 
protein was determined by Western blotting. PE, phenylephrine; NRVM, neonatal rat 
ventricular myocytes.  
Supplemental Reference: 
1. Ota A, Zhang J, Ping P, Han J, Wang Y. Specific regulation of noncanonical p38α
activation by hsp90-cdc37 chaperone complex in cardiomyocyte. Circulation
Research. 2010;106:1404-1412.
